GILDD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.50 |
| 52 Week High | US$25.15 |
| 52 Week Low | US$15.50 |
| Beta | 0.20 |
| 1 Month Change | 7.93% |
| 3 Month Change | 18.07% |
| 1 Year Change | 2.08% |
| 3 Year Change | 32.79% |
| 5 Year Change | n/a |
| Change since IPO | -98.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| GILDD | AR Biotechs | AR Market | |
|---|---|---|---|
| 7D | 2.9% | 0% | 0% |
| 1Y | 2.1% | 0% | 0% |
Return vs Industry: GILDD exceeded the AR Biotechs industry which returned -2% over the past year.
Return vs Market: GILDD underperformed the AR Market which returned 132.1% over the past year.
Price Volatility
| GILDD volatility | |
|---|---|
| GILDD Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: GILDD's share price has been volatile over the past 3 months compared to the AR market.
Volatility Over Time: GILDD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of AR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILDD fundamental statistics | |
|---|---|
| Market cap | US$115.37b |
| Earnings (TTM) | US$126.00m |
| Revenue (TTM) | US$28.30b |
915.6x
P/E Ratio4.1x
P/S RatioIs GILDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILDD income statement (TTM) | |
|---|---|
| Revenue | US$28.30b |
| Cost of Revenue | US$6.28b |
| Gross Profit | US$22.02b |
| Other Expenses | US$21.89b |
| Earnings | US$126.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 77.80% |
| Net Profit Margin | 0.45% |
| Debt/Equity Ratio | 126.4% |
How did GILDD perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield3,027%
Payout RatioDoes GILDD pay a reliable dividends?
See GILDD dividend history and benchmarks| Gilead Sciences dividend dates | |
|---|---|
| Ex Dividend Date | Dec 13 2024 |
| Dividend Pay Date | Dec 30 2024 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 8 days |
Does GILDD pay a reliable dividends?
See GILDD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 08:44 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gilead Sciences, Inc. is covered by 75 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |